Mcm. Finnegan et al., MDR-1 EXPRESSION IN NON-HODGKINS-LYMPHOMAS IS UNRELATED TO TREATMENT INTENSITY OR RESPONSE TO THERAPY, Leukemia & lymphoma, 18(3-4), 1995, pp. 297
Over-expression of the MDR-1 gene, which codes for P-glycoprotein, is
thought to be an important mechanism in the drug resistance exhibited
by many tumours. A number of chemotherapeutic agents which induce MDR-
1 expression are also components of combination chemotherapies that ar
e used in the treatment of high grade non-Hodgkin's lymphomas (NHL). W
e have therefore examined expression of MDR-1 in a series of NHL by No
rthern blot analysis as well as investigated the localization of P-gly
coprotein by immunohistochemistry. The series included 11 hyperplastic
reactive nodes and tonsils, 17 low grade NHL and 15 high grade NHL. T
he levels of MDR-1 mRNA were quantified by scanning densitometry and c
omparison with levels of glucose-6-phosphate dehydrogenase (G6PD). The
MDR-1 mRNA was observed in both non-malignant and NHL tissues. Immuno
histochemical staining revealed that expression of MDR-1 mRNA in react
ive nodes was related to the presence of P-glycoprotein in lymphocytes
, however, P-glycoprotein was apparent in both the reactive lymphocyte
s and tumour cells in the NHL samples. Elevated mRNA levels (2-3 fold
increase) were observed in some low grade and high grade NHL relative
to those observed in reactive lymphoid tissue. There appeared to be li
ttle correlation, however, between expression of the MDR-1 gene and ei
ther treatment intensity or response to therapy. The drug resistance t
hat is often encountered in NHL patients is therefore likely to involv
e mechanisms other than over-expression of P-glycoprotein.